awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35603657-5F56BA9F-2D81-4963-B602-3E5D9F8EE19D
Q35603657-5F56BA9F-2D81-4963-B602-3E5D9F8EE19D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35603657-5F56BA9F-2D81-4963-B602-3E5D9F8EE19D
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.
P2860
Q35603657-5F56BA9F-2D81-4963-B602-3E5D9F8EE19D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35603657-5F56BA9F-2D81-4963-B602-3E5D9F8EE19D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
633cd1c182e6f8ba707e2e48842cf8df8c476af3
P2860
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential